Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Generics Director’s Departure Shows Why Chemistry Matters

Executive Summary

Another outside candidate is expected to eventually take over for the departing director Gregory Geba, and while the Office of Generic Drugs can run smoothly without a permanent leader for now, it cannot do so forever.


Related Content

FDA’s Generics Office Loses Another Director As Geba Makes Quick Exit
CDER Taps Genzyme Exec As Deputy Director For Science Operations
GDUFA Self-Identification Woes Can’t Deflate Industry, FDA Enthusiasm
Boehringer Ingelheim’s Me-Too Petition Against Generic Spiriva
Backlog Backfire: FDA Sees Increase In Pending Generic Applications At Deadline
Clinical Trials Not Required For Lidoderm Generics, FDA Tells Endo
FDA Office Of Generic Drugs Director Has Brand Industry Background
FDA's Woodcock Expresses Concern Not All Generics Are Equivalent, But OGD May Have Solution
FDA's Buehler To Join Teva
FDA's Generic Drugs Office Faces Transition As Director Buehler Departs


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts